New Therapy Stops Seizures in Mouse Model of Rare Childhood Epilepsy

SCN8A encephalopathy could be improved with a treatment already approved for other uses.

5:00 AM

Author | Kelly Malcom

2020 SCN8A Malcolm

Seizure disorders in babies are frightening and heartbreaking. A new basic science breakthrough offers hope for a potential treatment for rare developmental and epileptic encephalopathies resulting from a single genetic mutation. The gene in question, called SCN8A, controls a sodium channel that allows neurons to transmit an electric signal.  When this gene is mutated, these channels can become hyperactive, resulting in recurrent seizures. The average age of onset of SCN8A-related encephalopathy is just four months old.

"Approximately half of patients are severely impaired and cannot walk or talk," says Miriam Meisler, Ph.D. Meisler is the Myron Levine Distinguished University Professor of Human Genetics and a Professor of Neurology at U-M Medical School. She and her team have studied this disease and its genetic mechanisms for many years, painstakingly developing mouse models that would allow for testing new therapies.

Within the past few years, a new therapy called antisense oligonucleotide (ASOs) has entered the scene, enabling researchers to control gene expression. ASOs are short DNA or RNA molecules designed to block messenger RNA molecules and their encoded proteins. This allows them to control the amount of RNA expressed by mutated genes, dampening their effects on the body.

MORE FROM THE LAB: Subscribe to our weekly newsletter

The team realized the potential of ASOs for this seizure disorder. Their first achievement was developing a mouse model that accurately and predictably mimicked the disease in people. They generated a mouse with the same SCN8A mutation found in several patients but with the mutation turned off long enough to test the therapy.

Developing mice with an "on switch", they were able to administer the ASO, and then turn on the mutation. "The effect was dramatic and unambiguous," says Meisler. "We had a four-fold increase in lifespan, with added effects of repeated treatments." There was no evidence of low-level seizure activity in the treated mice.

The amount of mRNA expressed was reduced by half after ASO treatment, which was well tolerated. The treatment was also effective against other types of epilepsy, including Dravet syndrome. They're currently testing other mouse models of seizure disorders to see how widespread the effectiveness might be, "This has the potential to go beyond sodium channel disorders," says Meisler. 

She notes that ASOs are already FDA approved for several disorders, including spinal muscular atrophy. "I think this will be a breakthrough for these devastating neurological conditions; they are now amenable to a truly personalized treatment."  The work is described in a recent publication in the Annals of Neurology.       

Like Podcasts? Add the Michigan Medicine News Break to your Alexa-enabled device or subscribe for updates on iTunesGoogle Play and Stitcher.

The work was completed in collaboration with the labs of Jack Parent, M.D., William J Herdman Professor of Neurology and Co-Director of Michigan Medicine's Epilepsy Program and Roman Giger, Ph.D., George Linius Streeter Collegiate Professor in the Department of Cell & Developmental Biology. Other U-M authors include: Guy Lenk, Sophie Hill, Lucas Huffman, Corrine Smolen, Jacy Wagnon, Hayley Petit, Wenxi Yu, Julie Ziobro, and Kritika Bhatia. Funding was provided by the National Institutes of Health/National Institute of Neurological Disorders and Stroke.

Paper Cited: "Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A Encephalopathy and Dravet Syndrome," Annals of Neurology. DOI: 10.1002/ana.25676


More Articles About: Lab Report Basic Science and Laboratory Research epilepsy Developmental Delay Genetic Disorders All Research Topics
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories white pills falling out of orange pill bottle on a brown surface
Health Lab
Drug combination reduces breast cancer risk and improves metabolic health in rats
Researchers investigated the combined effects of bazedoxifene and conjugated estrogens in rat models as an alternative to tamoxifen.
RNA strand in purple on black background
Health Lab
A structural biologist weighs in on the tricky task of determining RNA’s shape
A recent article in Nature details why the quest to determine the shapes of RNA is difficult even for artificial intelligence.
mouse seeing three cookies with red dots out of brain
Health Lab
Researchers use nanoparticles to target glioblastoma in mice
University of Michigan researchers have created nanodiscs that can target cholesterol levels in GBM, starving the cancer cells and increasing survival rates of the treated mice.
doctors drawn looking at big oversized lungs
Health Lab
The most effective prevention method for complications post lung transplant
Out of the two most common treatments for chronic lung allograft dysfunction, a condition that can form after lung transplantation that has no treatment, a study from University of Michigan Health found that cyclosporine is not as effective as tacrolimus in preventing the condition.
blood vessel up close with red cells and yellow inside
Health Lab
Drug candidate successfully treats atherosclerosis, fatty liver disease in large mammals 
A compound that was previously found to treat severe fatty liver disease also reduces atherosclerosis, a primary driver of cardiovascular death, in non-human primates. The drug candidate was developed at the University of Michigan.
ultrasound scan on yellow background with red dot found in two images
Health Lab
Using ultrasound technology to quickly diagnose giant cell arteritis
Ultrasound technology at University of Michigan Health is helping diagnose giant cell arteritis in patients to begin potentially moving away from using invasive surgical biopsy methods.